At Clasp Therapeutics, we are expanding the reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. This approach enables a highly selective paradigm where every patient has the opportunity to respond to treatment.
Market
Immuno-oncology
Location
Rockville,
MD,
USA
Coinvestors
Alexandria Venture Investments, Blackbird Ventures, BrightEdge Fund, Catalio Capital, Cure Ventures, Novo Holdings, Pictet, Third Rock Ventures, Vivo Capital